New paradigms in the recognition and acute treatment of migraine (Q34634345)

3 August 2017

1 reference

title

New paradigms in the recognition and acute treatment of migraine (English)

1 reference

3 August 2017

1 reference

2

Stewart J Tepper

1 reference

3 August 2017

Fred D Sheftell

1

1 reference

3 August 2017

publication date

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

42

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

58-69

1 reference

2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Validation of a new instrument for determining migraine prevalence: the UCSD Migraine Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Migraine Symptoms: Results of a Survey of Self‐Reported Migraineurs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

A long-term study to maximise migraine relief with zolmitriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Serotonin 5-HT1B/1D Receptor Agonists in Migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

The clinical profile of sumatriptan: efficacy in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Naratriptan: biological profile in animal models relevant to migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Acute migraine treatment outcome measures: a clinician's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Oral almotriptan in the treatment of migraine: safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2002.02015.X

10.1046/J.1526-4610.2002.02015.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference